Chronic Ulcer of Lower Extremity
Conditions
Keywords
Diabetic ulcer, Venous stasis ulcer
Brief summary
The purpose of this study is to assess the safety and preliminary efficacy of PalinGen® Flow for the treatment of chronic ulcers of the lower legs and feet.
Interventions
BIOLOGICALPalinGen Flow Amniotic Tissue Allograft
Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.
Sponsors
Amnio Technology, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Able to read, understand and sign the informed consent form (ICF) * Available and willing to complete all study assessments * At least 12 weeks post lower extremity revascularization procedure, if one has been performed * Have chronic ulcer(s) of the lower extremities with the following characteristics: * Of diabetic or vascular etiology * Duration of ≥4 weeks, unresponsive to SOC * ≤20 cm2 in area * Extend through the full thickness of the skin but not down to muscle, tendon, or bone * For subjects with VLU: * Ulcer area is ≥1.5 cm2 and ≤20 cm2 and with a clean, granulating base with minimal adherent slough * Ulcer location is at or above the ankle (malleolus) and below the knee * Ulcer location is appropriate for use of compression therapy treatment * For subjects with DFU: * Ulcer area is ≥1.5 cm2 and ≤ 20 cm2 and is amenable to off-loading * Subject has diabetes mellitus (Type 1 or Type 2), requiring insulin or oral/injectable medications to control blood glucose levels * Glycosylated hemoglobin (HbA1c) level at screening is \<12% * Adequate circulation to the affected lower extremities * Total serum bilirubin, alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), hemoglobin, WBC, and PLT count all within limits specified in study protocol * No renal impairment or mild renal impairment, defined as creatinine clearance ≥50 mL/min (by Cockroft-Gault estimation) * Male subjects and female subjects of childbearing potential must use acceptable methods of contraception
Exclusion criteria
* Clinical evidence of ongoing infection and/or receipt of IV, oral, or topical antimicrobials at the Baseline Visit * Wheelchair bound or bed-ridden (ambulatory with assistance is acceptable) * Ulceration at the site of amputation * Undergoing renal dialysis * Known or suspected malignancy in the target ulcer, or a history of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancer) * Documented history of osteomyelitis at the target ulcer location within 6 months of screening * Current treatment or anticipated need for treatment over the course of the study with: * Immunosuppressants (including topical or systemic corticosteroids or glucocorticoids) * Cytotoxic chemotherapy * Growth hormone * Oral or systemic antifungal or antituberculosis treatment * History of radiation at the ulcer site * New York Heart Association Class III or IV congestive heart failure or uncontrolled cardiac dysrhythmia * Diagnosis of autoimmune disease(s) (rheumatoid arthritis, lupus, psoriasis, Sjogren's syndrome) or arthritis requiring corticosteroid treatment * Target ulcer(s) previously treated with negative pressure, hyperbaric oxygen, or tissue engineered materials (eg, Apligraf®, EpiFix® or Dermagraft®) or other scaffold materials (eg, Oasis, Matristem) within 4 weeks prior to Screening Visit * Target ulcer(s) anticipated to require negative pressure wound therapy or hyperbaric oxygen at any time during the study * Subjects with VLU who have: * Deep vein thrombosis diagnosed within 4 weeks prior to Screening Visit * Refusal or inability to tolerate compression therapy * Subjects with DFU who have: * Active Charcot foot (stable chronic Charcot foot is not exclusionary) * Ulcers on toes 2, 3, 4, and/or 5 only (ulcer on plantar surface of the great toe only is not exclusionary) * Pregnant or breast feeding * Allergic to DMSO * Healing of target ulcer is observed to be ≥35% at the end of the Run-in Period (between Screening and Baseline Visits) * Presence of any condition(s) which compromises the subject's ability to complete this study, including subjects with a known history of poor adherence to medical treatment * Subjects who, in the opinion of the Investigator, are not able to comply with study requirements * Treatment with an investigational drug(s) or device(s) within the 4 weeks preceding Screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of participants in the PalinGen Flow plus SOC group versus SOC alone with treatment-emergent adverse events (TEAEs) | All adverse events (AEs) and serious adverse events (SAEs) will be recorded from the time of signing of the informed consent form through Week 64. | Treatment-emergent adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and graded per the CTCAE Version 5.0. |
| Proportion of participants in the PalinGen Flow plus SOC group versus SOC alone who achieve complete ulcer closure by Week 12. | BWAT assessment and wound imaging will be performed at each study visit through end of treatment (Week 12) | Complete wound closure will be assessed by the Bates-Jensen Wound Assessment Tool (BWAT) and a photographic imaging and measurement device. |
Countries
United States
Outcome results
None listed